In NSCLC patients treated with PD(L)1 inhibitors, a high proportion (>40%) of highly differentiated CD4 T cells (CD27−CD28 low/negative) in peripheral blood at baseline could predict objective RR with 100% specificity and 70% sensitivity [40]. Here, CD4 is linked to non-small cell lung carcinoma.